Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.
Also called NCT02827708
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 324 participants
- Sponsor
- Registry
-
NCT02827708 -
2015-005326-19
-
- Other papers using this trial's data
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Denmark, Finland, Israel, Poland, Russia, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02827708. Randomized; double masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2018-04-10 (actual). Results posted on 2020-02-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
- Acronym
- PIONEER 5
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02827708- Content hash
fb281162a77dfc37dc52f9f31d066305a8b8cfce9ef2cdc7a1219f18d479aa19